KEMPOWER
1.7.2021 12:58:11 CEST | Business Wire | Press release
Kemppi Group Oy, the owner of Kempower Oy, acquires a business property managed by S-Bank Properties, including 10 300 m2 of factory space. The new facility will enable Kempower to scale up production by approximately 500% compared to its current capacity. Kempower will gradually ramp up production in 2021-2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005423/en/
Kempower, a leading e-mobility charging technology provider in the Nordics, responds to the rapidly growing e-mobility market demand by scaling up production gradually by the end of 2022. Kemppi Group Oy, the owner of Kempower Oy, acquires a business property including 10 300 m2 of factory space. The business property includes extensive unused building right to further expand production in the future. The seller in the transaction is the insurance group Fennia, for which S-Bank's subsidiary S-Bank Properties Ltd provides real estate portfolio management and administration services.
The factory, originally built in 2007 and expanded in 2020, is located in Rälssinkatu 1, Lahti, Finland, with excellent transport connections. Kemppi Group will lease the factory to Kempower. The new facility will enable Kempower to expand its production by approximately 500% compared to the current capacity. Kempower’s production will be scaled up for the second time in a short time: at the beginning of 2021, Kempower increased its production by five times from the 2020 level.
“As Kempower’s owners, we are very committed to the company. Kempower has a lot of growth potential and the international EV charging market has reacted positively to Kempower’s DC charging offering. With this investment, we want to ensure Kempower’s ability to respond to the market demand”, states Antti Kemppi , Chairman of the Board of Kemppi Group & Kempower.
”We are particularly pleased to be able to continue the life of this valuable business property and to provide new jobs in the Lahti region”, Antti Kemppi adds.
“It’s great that this well-kept property found a new home. I believe that the site's modern production facilities offer a great platform to develop business in the future” says Harri Oravainen , Real Estate Investment Director, S-Bank Properties.
“Our aim is to be the preferred partner in the world in developing emission-free business. Our ultimate goal is to create an EV charging infrastructure so extensive and reliable, that the electric vehicles can and will be the new reality. With the new facility, we are able to support our customers in developing emission-free business even faster than before”, states Tomi Ristimäki , CEO, Kempower.
“In the new facility, Kempower will have all the essential functions in one location, including production, R&D, laboratory, testing and offices. The new facility will allow us to be efficient and agile as all the teams will be working seamlessly under one roof”, says Tomi Ristimäki , CEO, Kempower.
The preparations for Kempower’s new facility will start immediately. To ensure customer deliveries, Kempower will gradually ramp up production in 2021-2022. All company functions will be moved to the new location by the end of 2022.
Catella Asset Management acted as Kemppi Groups’ buyside advisor and HPP Attorneys as legal advisors on the transaction.
Kempower designs and manufactures DC fast charging solutions for electric vehicles and machines operating in the most demanding conditions. We are a largescale charging system supplier, aiming for a smoothly running electric mobility infrastructure. With 70 years of experience in perfecting power sources, we set the bar high in engineering and user-experience design. Over 90% of our materials & components are sourced from Finland. Kempower DC charging solutions are designed and manufactured in Lahti, Finland, and available globally. www.kempower.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005423/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom